Antibody Therapeutics Xchange West Coast 2019
- What is the situation?
- Swiss Army Knife Approach: piling multiple non-dependent targets on a single molecule
- MoA completely depends on BiS
- MoA may be enhanced by BiS
- Early regulatory and CMC advantages may come back to bite you in later stages
- Is there a future regulatory path for recombinant polyclonal therapeutics?
- Optimal discovery method versus available budget – how do we decide the best path?
- Animal immunizations, natural human antibody repertoire library selection, or synthetic library selection – what are the pros and cons?
- What is the best strategy for choosing the lead candidate selection criteria and at what point should a functional study be integrated – early or later?
- What are the ideal immunization and selection tools? If appropriate cell lines and/or recombinant proteins are not available?
Director of Sales
Barry Duplantis received a double major in Biochemistry and in Chemistry, and his Ph.D. in Microbiology from the University of Victoria in 2011, where he specialized in intracellular pathogenesis, bacterial genetics and synthetic biology. He subsequently founded and was CEO of DuVax Vaccines and Reagents Inc, a biotechnology company that specialized in the development of bacterial vaccines. Under Barry, DuVax successfully entered into collaborative research projects with two major pharmaceutical companies and delivered vaccines candidates for two separate pilot studies. He has also sat on the advisory board of biotechnology companies in the Victoria and Vancouver, B.C. areas.
- What does it mean (to you) to validate a target?
- What alternative criteria are used to justify discovery on a non-validated target?
- Can an imperfect animal model stand in the way of a perfectly good drug?
- When is a cell-based model superior to an animal model?
Alan is experienced with pre-clinical biologic drug discovery campaigns for a wide range of targets. He has served as project leader and engineering lead for both antibody and non-antibody biologic drug candidates.
Prior to NGM, Alan received his Ph.D. from UC San Diego for investigations of transcriptional regulation, post-doctoral training at UCSF, and then stints with Roche (Palo Alto), and Altravax.
- How do you nominate a potential drug target?
- How do you rate target tractability?
- What do you require before committing any resources to investigate a target?
- How do you deal with competing priorities within you discovery group?
- How early do you engage other groups in target prioritization (translational, Non-Clinical, Clinicaland business development?
Head of Antibody & Assay Development
Robin has been involved in the development of monoclonal antibodies for over 25 years. At Elan, she headed the group that developed both the murine version of Natalizumab for Multiple Sclerosis and Bapineuzumab for Alzheimer’s Disease. At Prothena, currently 2 additional antibodies developed by her group are in Clinical Trials, one for the treatment of Parkinson’s Disease in Phase II, and the other for the treatment of TTR amyloidosis in phase I. Additionally, her group develops all pre-clinical and clinical assays for PK, ADA and biomarkers needed for Prothena’s programs.